SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC grew its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 30.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,760 shares of the company’s stock after acquiring an additional 14,548 shares during the period. Los Angeles Capital Management LLC owned about 0.08% of SpringWorks Therapeutics worth $2,231,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC purchased a new position in SpringWorks Therapeutics in the 4th quarter valued at approximately $45,000. Principal Financial Group Inc. increased its position in shares of SpringWorks Therapeutics by 20.2% in the fourth quarter. Principal Financial Group Inc. now owns 1,103,858 shares of the company’s stock valued at $39,882,000 after buying an additional 185,413 shares in the last quarter. State of New Jersey Common Pension Fund D raised its stake in shares of SpringWorks Therapeutics by 19.3% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 55,343 shares of the company’s stock worth $2,000,000 after buying an additional 8,954 shares during the last quarter. Rhumbline Advisers raised its stake in shares of SpringWorks Therapeutics by 2.3% during the 4th quarter. Rhumbline Advisers now owns 101,904 shares of the company’s stock worth $3,682,000 after buying an additional 2,251 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of SpringWorks Therapeutics by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,773 shares of the company’s stock worth $570,000 after buying an additional 1,488 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Wedbush restated an “outperform” rating and set a $81.00 target price on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a report on Friday, February 21st. Evercore ISI boosted their price target on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Finally, Guggenheim lowered their price target on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $71.50.

SpringWorks Therapeutics Stock Performance

SWTX opened at $53.41 on Friday. SpringWorks Therapeutics, Inc. has a 1 year low of $28.21 and a 1 year high of $62.00. The firm has a 50 day moving average price of $42.53 and a 200 day moving average price of $38.18. The company has a market cap of $4.00 billion, a PE ratio of -15.35 and a beta of 0.81.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings data on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The business had revenue of $61.55 million during the quarter, compared to analyst estimates of $60.53 million. On average, sell-side analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Insider Activity at SpringWorks Therapeutics

In other news, COO Badreddin Edris sold 20,000 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total value of $839,400.00. Following the completion of the sale, the chief operating officer now owns 209,600 shares of the company’s stock, valued at $8,796,912. This represents a 8.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Daniel Lynch sold 175,000 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $54.46, for a total value of $9,530,500.00. Following the sale, the director now owns 130,944 shares in the company, valued at approximately $7,131,210.24. The trade was a 57.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 391,766 shares of company stock worth $21,499,996. Corporate insiders own 7.61% of the company’s stock.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.